Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo

NCT ID: NCT04539067

Last Updated: 2020-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-01

Study Completion Date

2021-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate and compare the efficacy of H FSH plus HMG Vs HMG alone on oocyte and embryo quality in IcsI patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

70 patients divided in to 2groups Group A controlled ovarian stimulation with H FSH and HHMg Group B controlled ovarian stimulation with HMG alone Results will be discussed later

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Stimulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HMG group

Induction of ovulation from 2nd day of cycle Follow diameter of follicle When follicle 18:22mm Receive HMG

Group Type EXPERIMENTAL

HHMG

Intervention Type DRUG

Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG

H FSH plus HHMG

Follow up ovulation from the 2nd day to 5th of menstruation cycle When follicle diameter 18mm to 22mm made induction of ovulation

Group Type EXPERIMENTAL

HHMG

Intervention Type DRUG

Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HHMG

Induction of ovulation from the 2nd day of cycle to 5th day then follow the diameter of follicle Use transvaginal ultrasound When diameter of follicle 18 to 22 patients receiving HMG

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Using HHMG for induction

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Infertil women aged from 20\_35yr
2. Normal utreus
3. Normal ovaries
4. unexplained infertility
5. no endometriosis

Exclusion Criteria

1 - poor responders to gonadotropin 2-Prior history of more than 3unsucceful ICSI 3-Any malformation of sexual organs
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Minia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marwa Bahgat Tarahony

Eygpt Minia

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marwa Ba Tarahony

Role: PRINCIPAL_INVESTIGATOR

Faculty of Medicine, Minia University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marwa Ba Tarahony

Role: CONTACT

01008160037

Kareem Ib Shaheen

Role: CONTACT

01210966045

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

635_5/2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Gonadotropin Type in Ovarian Stimulation
NCT02437032 COMPLETED PHASE4